key: cord-0958687-w5mjwfep
authors: McKeigue, P. M.; Colhoun, H. M.
title: Evaluation of "stratify and shield" as a policy option for ending the COVID-19 lockdown in the UK
date: 2020-04-30
journal: nan
DOI: 10.1101/2020.04.25.20079913
sha: 2bee78b3fff5d93b40bfecb41ee50e14cfc1dedd
doc_id: 958687
cord_uid: w5mjwfep

Although population-wide lockdowns have been successful in slowing the COVID-19 epidemic, there is a consensus among disease modellers that keeping the load on critical care services within manageable limits will require an adaptive social distancing strategy, alternating cycles of relaxation and re-imposition until a vaccine is available. An alternative strategy that has been tentatively proposed is to shield the elderly and others at high risk of severe disease, while allowing immunity to build up in those at low risk until the entire population is protected. We examine the performance required from a classifier that uses information from medical records to assign risk status for a such a stratify-and-shield policy to be effective in limiting mortality when social distancing is relaxed. We show that under plausible assumptions about the level of immunity required for population-level immunity, the proportion shielded is constrained to be no more than 15% of the population. Under varying assumptions about the infection fatality ratio (from 0.1% to 0.4%) and the performance of the classifier (3 to 4.5 bits of information for discrimination), we calculate the expected number of deaths in the unshielded group. We show that with likely values of the performance of a classifier that uses information from age, sex and medical records, at least 80% of those who would die if unshielded would be allocated to the high-risk shielded group comprising 15% of the population. Although the proportion of deaths that would be prevented by effective shielding does not vary much with the infection fatality ratio, the absolute number of deaths in the unshielded varies from less than 10,000 if the infection fatality rate is 0.1% to more than 50,000 if the infection fatality rate is as high as 0.4%. For projecting the effect of an optimally applied stratify-and-shield policy, studies now under way should help to resolve key uncertainties: the extent to which infection confers immunity, the prevalence of immunity, the infection fatality ratio, and the performance of a classifier constructed using information from medical records. It is time to give serious consideration to a stratify-and-shield policy that could bring the COVID-19 epidemic to an end in a matter of months while restoring economic activity, avoiding overload of critical care services and limiting mortality.

The Sars-CoV-2 epidemic will be over only when the level of immunity in the 32 population reaches a level where the effective reproduction number falls below 1 through 33 natural immunity or vaccination. It is expected to be at least a year before an effective 34 vaccine can be developed and tested adequately. On 23 March 2020 stringent social 35 distancing measures (termed lockdown) were imposed in the UK so as to prevent the 36 epidemic from overwhelming the National Health Service and to reduce immediate 37 impact on deaths. Modelling studies for the Scientific Pandemic Influenza Group on 38 Modelling (SPI-M) have suggested that an adaptive strategy "alternating between 39 periods of more and less strict social distancing measures" may be needed to keep the 40 number of critical care cases within capacity until the epidemic ends [1] . Concern about 41 the economic and social costs of this intermittent lockdown strategy has motivated 42 exploration of other approaches for managing the epidemic from this point forward. 43 One suggested strategy for exit from the lockdown has been to undertake weekly 44 testing of the entire population for SARS-CoV-2 RNA, followed by isolation of those 45 who test positive and their contacts until the epidemic is suppressed [2] . Another option 46 that has been tentatively proposed is to shield those at high risk while allowing 47 immunity to build up in those at low risk [3] . A a briefing dated 26 February from the 48 Scientific Advisory Group on Emergencies (SAGE) alluded to this "stratify-and-shield" 49 approach [4] : 50 An additional strategy would be to apply more intense measures on those age 51 or risk groups at most risk of experiencing severe disease (e.g. household 52 isolation of those over 65, special measures around care homes). The has not looked at the likely feasibility or effectiveness of such methods. 56 In subsequent modelling studies for SPI-M, interventions including less stringent 57 "social distancing" of those over 70 years of age were assessed based on assuming modest 58 reductions in contacts with people outside the household but no reduction in household 59 contacts [5] . The models predicted that although this partial shielding would be one of 60 the most effective measures in reducing total deaths and severe outcomes, under the 61 assumption of an infection fatality ratio of 0.9% it would not be enough to prevent 62 critical care facilities from being overwhelmed. 63 A key objective of the emerging discipline of "precision medicine" is to use risk 64 stratification to assist clinical decision making. This has driven forward methodological 65 developments for instance in privacy-preserving analysis of information from medical 66 records, and quantifying increments in predictive performance in ways that are relevant 67 to decisions. As researchers in this field we have examined how risk stratification, based 68 on using information from medical records to quantify risk of severe or fatal COVID-19, 69 might lay the basis for a stratify-and-shield policy. We do not advocate a particular 70 course of action but instead investigate the theoretical dependencies of the 71 stratify-and-shield approach, its possible impact on mortality and workload for the 72 health service, and discuss how to resolve some of the key uncertainties upon which the 73 effectiveness of such an approach depends. ratio. The classifier is applied to the susceptible population, considered as a mixture of 84 "cases" (individuals who are destined to die if unshielded during the epidemic) and 85 "non-cases" (individuals who are destined to survive if unshielded during the epidemic). 86 Those at high risk are allocated to shielding until the epidemic among unshielded 87 individuals is over, by which time the proportion of unshielded survivors who are 88 immune has reached I u . We assume conservatively that by this time all unshielded 89 individuals who were destined to die if unshielded have died.

Write p 0 for the proportion of non-cases correctly classified as low risk (specificity of 91 the classifier) and p 1 for the proportion of cases incorrectly classified as low risk (1 92 minus sensitivity of the classifier).

Of the original population: is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 30, 2020. .

Calculating the predictive performance of a risk classifier from 101 the expected weight of evidence 102 To stratify people by risk, a classifier based on age, sex, other demographic variables 103 and medical history can be constructed. For each individual, such a classifier will 104 output the log-likelihood ratio (weight of evidence) favouring case over non-case status. 105 To predict how such a classifier will behave when used for risk stratification, we can use 106 the properties of the class-conditional sampling distributions of the weight of evidence 107 favouring assignment to one class over the other. These distributions are constrained by 108 mathematical consistency to have regularity properties [6] . The expectation of the 109 weight of evidence favouring the correct over the incorrect class assignment is the 110 expected information for discrimination conveyed by the classifier, denoted by the 111 symbol Λ [7] . A key advantage of using Λ, rather than the familiar C-statistic (area 112 under the receiver operating characteristic curve) to quantify classifier performance is 113 that the contributions of independent predictors are additive on the scale of Λ. We can 114 thus add the information for discrimination estimated from a case-control study 115 matched on age and sex to the information for discrimination calculated from age-and 116 sex-specific incidence rates.

If the classifier is constructed from many independent variables, the class-conditional 118 sampling distributions of the weight of evidence favouring case over non-case status will 119 be asymptotically Gaussian. In this situation the weight of evidence favouring case over 120 non-case status in cases, and the weight of evidence favouring non-case over case status 121 in non-cases will both be distributed with mean Λ and variance (when natural 122 logarithms are used) 2Λ. As described elsewhere, this result allows us to calculate how 123 the classifier will behave when used for risk stratification in the population, using only 124 the value of Λ [7] . To facilitate intuitive interpretation, we use logarithms to base 2 so 125 that Λ is expressed in bits (binary digits).

For a cut-off value of w bits for the weight of evidence favouring case over non-case 127 status,

For a given value of the classifier performance Λ, the infection fatality ratio F , and 131 and the proportion S who are susceptible at the outset, we can find by iteration the 132 value of w that will set the proportion of the population allocated to shielding to 0.15. 133 From this we can calculate the specificity p 0 and the sensitivity (1 − p 1 ) of the classifier 134 at this threshold. The stratify-and-shield policy is intended to achieve population-level immunity quickly 138 so that shielding of high-risk individuals can end. If in the surviving population at the 139 end of the shielding period the proportion who were shielded is P and the proportion of 140 unshielded individuals who are immune is I u P , the proportion I t of the total population 141 who are immune will be give by I t = (1 − P ) I u . The threshold value of I t required to 142 maintain population-level immunity is given by 1 − 1/R 0 , where R 0 is the case 143 reproduction number in a fully susceptible population [8]. This imposes a limit on the 144 proportion of individuals who can be allocated to shielding, as otherwise when shielding 145 April 25, 2020 4/12 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2020. . ends the mixing of shielded individuals who are still susceptible will dilute the 146 proportion I t of the total population who are immune below this threshold.

Estimates of R 0 have ranged from 2.5 [9] to 5.7 [10] . For this initial evaluation we 148 assume R 0 = 4, giving a threshold of I t = 0.75, and we assume also that the final 149 proportion I u of unshielded individuals who are immune will be driven to 0.9 by 150 overshoot of new infections after the threshold for population-level immunity has been 151 reached. It follows that for I t to be at least 0.75, P must be no more than 0.17. We 152 have therefore set 15% as an upper limit for the proportion of the original population to 153 be shielded under a stratify-and-shield policy. immune from 20% to 5% corresponds to varying the infection fatality ratio F from 0.1% 166 to 0.4%.

Information for discrimination obtained with a classifier using 169 age and sex only 170 We fitted a logistic regression model for the dependence of death from COVID-10 on 171 age and sex, using the age-sex distribution of all deaths with mention of COVID-19 up 172 to 18 April and population data for England and Wales. The odds ratio for death 173 associated with a ten-year increase in age was 3 and the odds ratio associated with male 174 sex was 2.1 The log-likelihood ratio favouring correct over incorrect assignment was 175 computed by subtracting the log prior odds from the log posterior adds. Taking the 176 average of this ratio (as the average of the mean in those who died and the mean in 177 those who survived) gives an estimate for the expected information for discrimination of 178 Λ = 3 bits. This provides a lower bound on a range of plausible values for the 179 performance of a classifier that uses information from medical records in addition to age 180 and sex: from associations with pre-existing morbidity we might expect to obtain 181 between 0.5 and 1.5 bits of information for discrimination. 183 For each assumed pair of values for infection fatality ratio F and and initial proportion 184 susceptible S, and each value of Λ, we calculated the threshold for sensitivity and 185 specificity that would set the the proportion of the population allocated to shielding to 186 0.15. From this we calculate the expected number of deaths in unshielded individuals, 187 under the conservative assumption that all those who are misclassified as low risk, and 188 thus advised to forgo shielding, die before the epidemic ends. We also calculated the 189 final proportion of the total population that is immune, given that the epidemic in the 190 April 25, 2020 5/12 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2020. . Table 1 shows the results of these calculations. The proportion p 1 is the proportion 195 of those destined to die who are incorrectly assigned to the unshielded group. The 196 sensitivity (1 − p 1 ) of the classifier, with threshold set so that 15% of the population 197 will be classified as high risk, is the maximal proportion of deaths that can be prevented 198 by a stratify-and shield-policy optimally applied, in comparison with an unselective 199 lifting of social distancing. The results show that even under unfavourable assumptions 200 -a classifier of modest performance and an infection fatality ratio as high as 0.4% -the 201 sensitivity of the classifier is at least 75%.

If the population-wide infection fatality ratio is as low as 0.1%, then even with a 203 classifier using that provides 3 bits of information for discrimination, equivalent to using 204 only age and sex, the mortality risk in unshielded susceptible individuals is less than 1 205 in 5000, though the total expected deaths in unshielded individuals is about 11,000 in If however the infection fatality ratio is as high as 0.15%, then a classifier of higher 212

April 25, 2020 6/12 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2020. . performance -4.5 bits -is required to keep the mortality risk in unshielded individuals 213 below 1 in 5000. If the infection fatality ratio is 0.2% or more, it is not possible even 214 using a classifier with Λ = 4.5 bits for a stratify-and-shield policy to keep the absolute 215 risk in unshielded individuals below this level.

Projected effect on critical care 217 From the ICNARC report on cases in critical care up to 16 April [11] we estimate that 218 the fatality rate in those aged under 69 years admitted to critical care with COVID-19 219 is 44%. This implies that for every 10,000 deaths in the unshielded group, there will be 220 about 24000 individuals requiring critical care. The average duration of stay of such 221 cases is about one week in the ICNARC data. Additional cases would be expected in The adaptive social distancing policy is intended to limit the arrival rate of severe cases 232 to a level that is within the capacity of critical care services to manage, and also to limit 233 deaths by delaying infection until a vaccine is available [5] . As updates of the original 234 modelling studies based on the rather lower values of the infection fatality ratio that are 235 now considered plausible [12] have not been released, it is difficult to make direct 236 comparisons between projections based on the adaptive social distancing policy and 237 those based on the stratify-and-shield policy. The projections above suggest that unless 238 the infection fatality ratio is higher than 0.2%, the stratify and shield policy should be 239 able to limit the arrival rate of severe cases to a level that is within the capacity of a estimates that a three-month lockdown will reduce UK GDP by 35 percent for one 246 quarter of the year [13] : this is about £194 billion. In the most favourable scenario for a 247 three-month lockdown, the epidemic is suppressed to very low levels until an effective 248 treatment or vaccine becomes available at the end of the lockdown. Under the least 249 favourable scenario for the stratify-and-shield policy in Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2020. . the most favourable scenario for the lockdown. For comparison, the National Institute 262 of Clinical Excellence uses £30,000 per year of healthy life gained as a cutoff for 263 deciding whether to recommend a new drug for the NHS. 265 We have shown that a stratify-and-shield policy would be constrained to shielding no 266 more than 15% of the population, but that even if a classifier using medical history 267 provided only a modest increment in predictive performance over one using only age The level of risk that might be considered acceptable at a collective level in exchange 277 for resuming economic and social activities is a policy decision. We note that the annual 278 risk of accidental death in England and Wales for men and women aged 30-64 years is 279 about 1 in 5000, and we do not stop the economy to prevent such deaths and neither do 280 individuals stay home to avoid such a risk. We note also that the projected mortality 281 risks in the unshielded are averages over the group; a risk classifier could of course 282 output not simply a dichotomous classification, but a continuous risk score that would 283 be the basis for individual choice. Any shielding strategy involves issues of ethics and 284 equity in that those in the unshielded group are asked to accept a low risk so that not 285 just they, but those shielded from infection, can emerge from isolation sooner.

It is to be expected that an epidemic in a susceptible population will overshoot the 287 threshold for population-level immunity, as even when the reproduction number falls 288 below 1 transmissions will continue for a few more generations till the epidemic is 289 extinguished. This overshoot is usually considered undesirable [3] , but for a 290 stratify-and-shield policy it is desirable to drive the level of immunity as high as 291 possible in the unshielded, so that when shielded individuals resume mixing the level of 292 immunity in the total populatio is not diluted below the threshold for herd immunity.

This in turn implies that the epidemic in unshielded individuals should be allowed to 294 run as fast as is compatible with not overloading critical care services, so as to maximize 295 the overshoot. Keeping the duration of the shielding period short will also help to 296 minimize the costs of shielding both to providers and to those shielded. The effect on 297 the epidemic of lifting social distancing restrictions after a lockdown is hard to predict, 298 and it is possible that the epidemic could peak rapidly such that half the severe cases 299 expected in unshielded individuals arrive within one month. In this scenario, 20,000 is 300 an upper limit on the total number of deaths during the shielding period that would not 301 overload critical care services.

For projections of the impact of a stratify-and-shield policy, the key uncertainties are 303 whether a single infection confers immunity, the infection fatality ratio, the predictive 304 performance of the classifier, and the effectiveness of shielding over the few months 305 required to allow the epidemic to run to completion in the low-risk group. We briefly 306 consider what is the extent of these uncertainties and how they might be resolved.

April 25, 2020 8/12

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2020. . https://doi.org/10.1101/2020.04. 25.20079913 doi: medRxiv preprint Does a single infection confer immunity? 308 Existing evidence on antibody-mediate immunity to coronaviruses has been reviewed 309 elsewhere [14] . A study of seasonal coronavirus infections based on the Flu Watch 310 cohort found no cases of reinfection with the same strain of coronavirus in a cohort of 311 216 adults with a first confirmed HCoV infection (0 of 8 individuals with two confirmed 312 infections) [15] . In a study of 18 patients with SARS, IgG antibodies to SARS were 313 reported to persist for at least 2 years [16] . Reinfection with SARS-CoV-2 could not be 314 induced experimentally with macaquess [17] . Antibody-dependent enhancement of acute 315 lung injury has been documented in experimental studies of SARS vaccines [18, 19] but 316 not with antibodies induced by infection with the SARS virus. As tens of thousands of 317 people have now tested positive for SARS-CoV-2, the most direct way to establish 318 whether repeat infection occurs is to link records of positive tests to identify recurrences 319 after recovery from the first infection.

Estimating the infection fatality ratio 321 The only direct estimate of the infection fatality ratio based on a population where all 322 individuals were tested and followed for mortality is from the Diamond Princess cruise 323 ship [20] , where there were 7 deaths among 634 passengers who tested positive. April that Public Health England was "testing samples of the population and is in the 330 process of analysing the first 800 samples collected" [21] , but the results had not been 331 published as of 25 April. Preliminary results of other seroprevalence surveys in Europe 332 and the US have been reported. Though the reliability of some of these studies has been 333 questioned [22] their findings are mostly consistent in showing seroprevalence levels 334 around 3-4% in the first week of April 2020. As the time from SARS-CoV-2 exposure to 335 seroconversion is estimated to be from 15 to 20 days [23] , the proportion infected by 336 late April is likely to be considerably higher than the seroprevalence in early April.

Practical feasibility of a stratify-and-shield policy 338 A detailed examination of the practical feasibility of a stratify-and-shield policy is 339 beyond the scope of this paper. Compliance (assumed to be voluntary) with shielding in 340 the high-risk group must be high enough that severe cases among those who forgo 341 shielding do not overload the health service, but unlike the adaptive social distancing 342 policy the stratify-and-shield policy would not require coercion. It does however require 343 that support for shielding is adequate to protect high-risk individuals from infection 344 while the epidemic in the unshielded group continues; if this support were implemented 345 in a half-hearted manner, the outcome for those who rely on social care would be poor. 346 Intense shielding is already recommended in UK guidance for more than 1 million 347 people who are "clinically extremely vulnerable" because they have received organ These individuals are advised to adopt rigorous shielding measures, including staying at 351 home at all times, isolating themselves from others in the same household and not going 352 out even for food or medicine. Assistance with delivery of food and medicines is offered 353 to people in this group.

The logistic challenges of providing this level of shielding to 15% of the population 355 are formidable, but not necessarily insurmountable if the duration of shielding is only a 356 few months. For instance, high-risk adults in crowded households might have to be 357 offered alternative accommodation until low-risk household members are immune, and 358 paid caregivers who are not already immune would need to be trained and equipped to 359 use reverse barrier precautions. Serological testing could be used to identify individuals 360 who are no longer susceptible as "focal points for sustaining safer interactions" with 361 those who are shielded [25] . Shielding of individuals who are in employment would 362 require guarantees that their employment status would not be jeopardized by isolating 363 themselves for a few months.

A stratify-and-shield policy using a classifier based on medical records has the potential 366 to save lives, restore economic activity and end the epidemic long before a vaccine is 

Scientific Advisory Group for Emergencies. SPI-M-O: Consensus view on behavioural 374 and social interventions

Universal weekly testing as the UK COVID-19 lockdown exit strategy. The Lancet

how do we minimize mortality for COVID-19 and other emerging infectious disease 383 outbreaks?

Scientific Advisory Group for Emergencies. Potential effect of non-pharmaceutical 385 interventions (NPIs) on a COVID-19 epidemic in the UK

Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and 392 healthcare demand

pdf: Imperial College COVID-19 Response Team

Coding theorems and weight of evidence

Quantifying performance of a diagnostic test as the expected 398 information for discrimination: Relation to the C-statistic

Herd immunity": A rough guide

How will 403 country-based mitigation measures influence the course of the COVID-19 epidemic

Release -High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome 407

Number 7July 2020 -Emerging Infectious Diseases

ICNARC. ICNARC report on COVID-19 in critical care

Global Covid-19 Case Fatality Rates

Office for Budget Responsibility. Commentary on the OBR coronavirus reference 418 scenario

Rattigan 422 SM, et al. A systematic review of antibody mediated immunity to coronaviruses

Antibody kinetics, correlates of protection, and association of antibody responses with 424 severity of disease

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63

Results from the Flu Watch cohort study

antibodies against SARS-coronavirus in SARS patients and their clinical significance

Reinfection could not occur 434 in SARS-CoV-2 infected rhesus macaques

SARS virus

Anti-spike IgG causes 441 severe acute lung injury by skewing macrophage responses during acute SARS

Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) 445 using age-adjusted data from the outbreak on the Diamond Princess cruise ship

Department of Health and Social Care. Coronavirus (COVID-19) Scaling up our 448 testing programmes

Antibody surveys suggesting vast undercount of coronavirus infections 452 may be unreliable

SARS-CoV-2 infection since the exposure and post symptoms onset